Cite
Jones SC, Ryan DL, Pratt VS, et al. Injection-Site Nodules Associated With the Use of Exenatide Extended-Release Reported to the U.S. Food and Drug Administration Adverse Event Reporting System. Diabetes Spectr. 2015;28(4):283-8doi: 10.2337/diaspect.28.4.283.
Jones, S. C., Ryan, D. L., Pratt, V. S., Niak, A., & Brinker, A. D. (2015). Injection-Site Nodules Associated With the Use of Exenatide Extended-Release Reported to the U.S. Food and Drug Administration Adverse Event Reporting System. Diabetes spectrum : a publication of the American Diabetes Association, 28(4), 283-8. https://doi.org/10.2337/diaspect.28.4.283
Jones, S Christopher, et al. "Injection-Site Nodules Associated With the Use of Exenatide Extended-Release Reported to the U.S. Food and Drug Administration Adverse Event Reporting System." Diabetes spectrum : a publication of the American Diabetes Association vol. 28,4 (2015): 283-8. doi: https://doi.org/10.2337/diaspect.28.4.283
Jones SC, Ryan DL, Pratt VS, Niak A, Brinker AD. Injection-Site Nodules Associated With the Use of Exenatide Extended-Release Reported to the U.S. Food and Drug Administration Adverse Event Reporting System. Diabetes Spectr. 2015 Nov;28(4):283-8. doi: 10.2337/diaspect.28.4.283. PMID: 26597395; PMCID: PMC4647172.
Copy
Download .nbib